Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Oct 19, 2013 10:07 AM Flag

    The hype that never was...Basher or biotech investor

    You can dismiss the sumpers nonsense about Huge! The share price was pumped dumped and churned and the shorts are here.Like every "next big presentation" or abstract, for investors,this was a non event.More informative? some notes perhaps but NTM is the next real news on tap so far,unless Insmed has to trial somewhere and spend that cash. Good Luck
    terry_insm posted
    "NACF ? the next big thing? really? You got the eposter presentation will be bubble gum all right,but will the data be favorable to the EU?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Reality check Aug 30 INSM $15.21 Oct 21 $15.21. and 100 posts from those who took no profits waiting for $25 soon! Ignore on 1 trade and Surfs up! INSM chart looks very good but the overall Market is squinky Good Luck

    • Folks took profits on Friday after a cconsiderable run in past weeks. If you believe that the poster was not meaningful, you are dumber than I thought. If you bet against Insmed over the next 6-12 months, you will probably get a good financial cleaning. But then again, you are on the sidelines so I doubt you have any money to loose. Stick around for the $20's. Soon enough. From $4-16 in less than 18 months. Next stop...,.

      Sentiment: Buy

      • 1 Reply to dorianrivers21
      • The issue for me is, given all of the interest from the EMEA, FDA and assorted countries, will this play out along the normally slow timelines or be accelerated. QDIP ad orphan status could translate into sales for NTM much sooner than what would normally be accepted and a quick approval for CF by the EMEA may lead to a much quicker ramp in the US. If, in fact, there are 50,000 patients waiting in the wings for NTM, twice that many for CF and hundreds of thousands more for other indications there may be $4-5 billion in revenue potential sooner than later. Then, of course, there's the potential for Iplex to replace Increlex for short stature and finally get to market for ALS and other potential licensing revenues. Has anyone done a net present value of the potential revues, profits and valuation given all of these things in the works?

        Sentiment: Buy

    • So, this happens with all stocks. What about those of us who bought and sold the move? I did:) as always, I missed the low and the high...but I took money to the bank...no one every went broke doing that....tool.

 
INSM
23.08+0.45(+1.99%)Apr 20 4:00 PMEDT